



Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

February 8, 2022

SAN DIEGO--(BUSINESS WIRE)--Feb. 8, 2022-- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that members of the Company's management team will be participating in the SVB Leerink 11th Annual Global Healthcare Conference 2022. Joseph Payne and Andrew Sassine, the chief executive and chief financial officers of Arcturus, respectively, will provide a corporate overview followed by a moderated Q&A on Friday, February 18th at 12:00 pm ET.

Conference: SVB Leerink Global Healthcare Conference
Presentation Date and Time: Friday, February 18, 2022, 12:00 PM ET
Registration: Link to presentation [here](#)

A [replay](#) of the corporate overview presentation and Q&A will be available on the [Events](#) section of the [Investor Relations website](#) after the conclusion of the presentation and will be archived on the website for 90 days.

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis along with partnered programs including glycogen storage disease type III (GSD III), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (with patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on [Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220207006010/en/): <https://www.businesswire.com/news/home/20220207006010/en/>

IR and Media Contacts

Arcturus Therapeutics
Deepankar Roy, Ph.D.
(858) 900-2682
IR@ArcturusRx.com

Kendall Investor Relations
Carlo Tanzi, Ph.D.
(617) 914-0008
ctanzi@kendallir.com

Source: Arcturus Therapeutics Holdings Inc.